Skip to main content

Cepheid Quietly Acquires microRNA Company Actigenics ...

NEW YORK (GenomeWeb News) – Cepheid today acquired Actigenics for an undisclosed sum, the company said today.
 
Cepheid acquired the French company for its microRNA portfolio. Actigenics possesses both therapeutic and diagnostic rights to validated microRNAs. Cepheid plans to out-license therapeutic applications of these microRNAs, the company said in a statement.
 
The microRNAs may potentially provide the basis for a broad range of proprietary markers for Cepheid in “cancer-specific markers, infection-specific markers, inflammation-specific
markers, and surrogate markers of complex regulatory mechanisms,” the company said.
 
Cepheid may also develop diagnostic tests associated with the therapeutic applications.
 
Financial details were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.